Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 8Brain Neoplasms 3Rare Tumor 1Radiation Pneumonitis 1Liver Diseases 1Digestive System Diseases 1Aumolertinib 1

Interventions

Temozolomide 73Bevacizumab 58Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × aumolertinib × Clear all
NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Unknown
54 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04905550 2021-06-02

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Chongqing University Cancer Hospital

Phase 2 Unknown
50 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04643847 2020-11-25

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

First People's Hospital of Hangzhou

Phase 2 Unknown
47 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡